Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024 11:07 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
Triyam Recognized on Inc. 5000 List for the Fourth Consecutive Year
August 15, 2024 09:00 ET
|
Access Information Management Shared Services, LLC
Company ranking leveled up 999 spots on this highlighted list of America’s Fastest-Growing Private Companies
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)
July 16, 2024 09:26 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented today studies supporting potential use of its novel drug IRX4204 for treatment of amyotrophic lateral sclerosis (ALS)
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
July 09, 2024 20:00 ET
|
Io Therapeutics, Inc.
Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
July 08, 2024 20:00 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes
AvePoint Named to Inc.’s Annual List of Best Workplaces for 2024
June 18, 2024 08:45 ET
|
AvePoint, Inc.
JERSEY CITY, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the global leader in robust data management and data governance, today announced it has been named to Inc.’s annual Best...
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List
April 09, 2024 09:15 ET
|
Lily AI
Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List.
With Extensive Two-Year Revenue Growth, ValueSelling Associates is Selected to Inc. Magazine’s List of the Pacific Region’s Fastest-Growing Private Companies
February 28, 2024 13:09 ET
|
ValueSelling Associates, Inc.
ValueSelling Associates has been selected to the Inc. 5000 Regionals Pacific list, showcasing the fastest-growing Pacific private companies.
Fundable for Life, Inc. Partners with The Latino Franchise Association to Provide its Clients TV and Digital Print Media Along with Funding Options
December 21, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Fundable for Life, Inc. Partners with Boston BioLife to Provide its Members TV and Digital Print Media Along with Funding Options
December 18, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.